Atrial Fibrillation
Large impact of remote screening tool on sleep apnoea diagnoses in AF

Inhaled flecainide promising for atrial fibrillation
NOAC could be better than warfarin in diabetes patients with atrial fibrillation
Apixaban plus P2Y12 inhibitor likely best for AF after ACS or PCI
New developments in remote diagnostics and monitoring of AF
Head-to-head: Efficacy of dabigatran versus warfarin on cognitive impairment
Posterior left pericardiotomy safe and effective in reducing atrial fibrillation
LAA ligation did not reduce recurrent atrial arrhythmias in persistent AF

Equal benefits of early rhythm control in AF subtypes

Atrial fibrillation symptoms less likely to be noticed by patients with diabetes
Women with breast cancer at increased risk for developing atrial fibrillation
Fitbit algorithm reliably detects atrial fibrillation
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine
Stroke risk rises transiently with AF episodes in patients with implanted cardiac devices

Healthy sleep patterns tied to healthier heart rhythms
Continuous monitoring detects atrial fibrillation up to 30 days after discharge

ESC 2021 Highlights Podcast
Drinking alcohol tied to increased atrial fibrillation risk hours later
Omecamtiv mecarbil might be less effective in patients with atrial fibrillation or flutter
Vericiguat effective irrespective of atrial fibrillation status
COVID-19 in AF patients with HF: no higher mortality but longer hospital stay

Psychoactive substances put young people at risk of cardiovascular disease
Can a glass of wine a day keep a-fib away?
Atrial fibrillation after SAVR or TAVR tied to poorer outcome
Apixaban has benefits over other DOACs in frail adults with atrial fibrillation
Athletes may have doubled A-fib risk compared to general public
Favourable outcomes with transcatheter atrial appendage occlusion

STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids

Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
With hypertrophic cardiomyopathy, age and BMI among predictors of AFib events
Ablation bests drug therapy for minorities with afib in North America
ECG biomarker identifies AFib patients most likely to benefit from electrical stimulation
EHRA Practical Guide on cardiac imaging in electrophysiology
Early rhythm-control ablation: insight from the CHARISMA registry
Personalised pulmonary vein isolation procedure feasible and effective
Pulmonary vein isolation: cryoballoon non-inferior to radiofrequency ablation
Predictors of young-onset atrial fibrillation
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Deep dive into EAST-AFNET 4 results on early rhythm-control in atrial fibrillation
Cryo-FIRST study: improved AF and QoL outcomes with cryoballoon versus drug therapy
STROKESTOP: Benefits of systematic screening for atrial fibrillation
DOACs and bleeding: the role of antidotes
2021 EHRA practical guide: DOACs in pre-operative and bleeding patients
Accelerometer-derived physical activity tied to atrial fibrillation risk
Finerenone may delay onset of atrial fibrillation in at-risk patients
Afib patients benefit when left-atrial-appendage occlusion added to their heart surgery
Anticoagulation common near end of life in dementia patients with AFib
Pulsed field ablation effective against paroxysmal atrial fibrillation
Catheter ablation likely more effective than drugs for paroxysmal atrial fibrillation
Many patients on DOACs receive concurrent non-indicated aspirin tied to bleeding risk
DOACs safer, more effective than warfarin in valvular atrial fibrillation
Screening with wearable ECG increased AF detection 10-fold in hypertensive older adults
AF monitoring following cardiovascular surgery
Pre-diabetes tied to increased stroke risk with nonvalvular atrial fibrillation
Vitamin D or omega 3 fatty acids do not prevent AF
Active screening for AF improves clinical outcomes
AF screening in older adults at primary care visits

Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
High blood pressure likely to be causally linked to atrial fibrillation
Left atrial appendage occlusion tied to less afib bleeding, mortality vs DOACs
Cryoablation Afib studies show better first-line outcomes than drug therapy
Rivaroxaban not inferior to warfarin for afib patients with artificial mitral valve
Direct oral anticoagulants may best vitamin K agonists for post-TAVR a-fib
Cryoballoon supplement to pulmonary-vein isolation curbs AF recurrence
2020 Atrial Fibrillation Guidelines
Reduced cardiovascular outcomes with early rhythm control
Drug initiation strategy not associated with increased use of oral anticoagulants
Digoxin improves symptoms in stable patients with permanent AF
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Factor V Leiden mutation linked to atrial fibrillation
Finding the sweet spot of anticoagulation in AF patients with ACS
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Infusion of ethanol in the vein of Marshall for persistent AF
Apple Heart Study: Not just for atrial fibrillation

Early apixaban safe as secondary prevention of stroke from AF
Lower rates stroke/SE with DOACs in frail non-valvular AF patients

Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Substantial impact of temporary interruptions of warfarin versus DOAC
